title: A dynamical perspective of CTL cross-priming and regulation: implications for cancer immunology.
abstract: Cytotoxic T lymphocytes (CTL) responses are required to fight many diseases such as viral infections and tumors. At the same time, they can cause disease when induced inappropriately. Which factors regulate CTL and decide whether they should remain silent or react is open to debate. The phenomenon called cross-priming has received attention in this respect. That is, CTL expansion occurs if antigen is recognized on the surface of professional antigen presenting cells (APCs). This is in contrast to direct presentation where antigen is seen on the surface of the target cells (e.g. infected cells or tumor cells). Here we introduce a mathematical model, which takes the phenomenon of cross-priming into account. We propose a new mechanism of regulation which is implicit in the dynamics of the CTL: According to the model, the ability of a CTL response to become established depends on the ratio of cross-presentation to direct presentation of the antigen. If this ratio is relatively high, CTL responses are likely to become established. If this ratio is relatively low, tolerance is the likely outcome. The behavior of the model includes a parameter region where the outcome depends on the initial conditions. We discuss our results with respect to the idea of self/non-self discrimination and the danger signal hypothesis. We apply the model to study the role of CTL in cancer initiation, cancer evolution/progression, and therapeutic vaccination against cancers.
authors.affiliation: Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue North, MP-665 Seattle, WA 98109, USA. wodarz@fhcrc.org
authors.forename: Dominik
authors.initials: D
authors.lastname: Wodarz
authors.forename: Vincent A A
authors.initials: VA
authors.lastname: Jansen
mesh_terms: D000818:Animals; D017951:Antigen Presentation / Q000276:immunology; D000938:Antigen-Presenting Cells / Q000276:immunology; D045142:Cross-Priming / Q000276:immunology*; D003602:Cytotoxicity, Immunologic; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology*; D008954:Models, Biological; D009369:Neoplasms / Q000276:immunology*; D017634:Self Tolerance; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology*; D014780:Viruses / Q000276:immunology